[Liz Highleyman, Douglas Dieterich, and Kenneth Sherman, CROI 2012 interview, Seattle, March 8, 2012. Video footage courtesy of IFARA]
Provided by HIVandHepatitis.com
Published on Monday, 12 March 2012 00:00 Written by Gregory Fowler
Hepatitis C was a major topic at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) last week in Seattle. Liz Highleyman from HIVandHepatitis.com spoke with Douglas Dieterich and Kenneth Sherman about advances in the field, with a focus on HIV/HCV coinfected patients.
The attention this year was apt, since an estimated one-third of people with HIV are coinfected with hepatitis C virus (HCV). Dieterich and Mark Sulkowski presented the first data on sustained virological response (SVR) using the recently approved HCV protease inhibitors boceprevir (Victrelis) and telaprevir (Incivek) plus pegylated interferon/ribavirin in HIV/HCV coinfected patients.
Researchers also discussed drug-drug interactions between HCV direct-acting antivirals (DAAs) and antiretroviral agents, as well as interferon-free combinations that may be available in the future.
3/12/12
Source
L Highleyman, D Dieterich, and K Sherman. HIV/HCV Coinfection News from CROI 2012. IFARA interview, Seattle, March 8, 2012.
Source
No comments:
Post a Comment